- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04034810
Sikkerhed og effektivitet af Silk Vista og Silk Vista Baby Flow Diverter til behandling af intrakraniel aneurisme (FIRST)
Sikkerhed og effektivitet af Silk Vista og Silk Vista Baby Flow Diverter til behandling af intrakraniel aneurisme, en observationel, prospektiv, enkeltarms-, international, multicenterundersøgelse.
The FIRST study is an observational, prospective, multi-center, international, single-arm, study. The aim of the study is to collect safety and efficacy information on the use of the silk vista and silk vista baby flow diverter in order to assess clinical safety and performance of the device for treating intracranial aneurysms.
All patients with intracranial aneurysm ruptured or unruptured, whatever the localization of the aneurysm, and treated with silk vista or silk vista baby, will be consecutively enrolled in the study.
The patient's inclusion and follow up in the study will occur as part of their usual standard of care.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiesteder
-
-
-
Liège, Belgien, 4000
- CHC Saint Joseph Liège
-
-
-
-
-
Bordeaux, Frankrig, 33000
- CHU de Bordeaux - Hôpital Pellegrin
-
Brest, Frankrig, 29200
- Hopital Cavale Blanche
-
Bron, Frankrig, 69677
- Hospices Civils de Lyon - Hôpital Neurologique
-
Caen, Frankrig, 14033
- CHU Caen, Radiologie interventionelle
-
Clermont-Ferrand, Frankrig, 63003
- Centre Hospitalier Universitaire Clermont Ferrand
-
Grenoble, Frankrig, 38043
- Centre Hospitalier Universitaire de Grenoble Alpes
-
Le Kremlin-Bicêtre, Frankrig, 94270
- Hôpital Kremlin Bicêtre
-
Limoges, Frankrig, 87000
- Chu Dupuytren Limoges
-
Marseille, Frankrig, 13009
- Hôpital Privé Clairval
-
Paris, Frankrig, 75651
- Pitié-Salpêtrière Hospital
-
Paris, Frankrig, 75019
- Fondation Rothschild
-
Rouen, Frankrig, 76000
- CHU Chalre Nicolle
-
Tours, Frankrig, 37044
- Centre Hospitalier Régional Universitaire de Tours
-
-
-
-
-
Nijmegen, Holland, 6525 G
- Radboud University medical Center
-
-
-
-
-
Jerusalem, Israel, 9112001
- Hadassah Medical Center
-
Nahariya, Israel, 22100
- Galilee Medical Center
-
-
-
-
-
Milan, Italien, 20162
- Niguarda Hospital
-
Monza, Italien, 20900
- San Gerardo Hospital
-
Treviso, Italien, 31100
- Cà Foncello Hospital
-
Udine, Italien, 33100
- Santa maria della misericordia hospital
-
-
-
-
-
Zagreb, Kroatien, 10000
- University Hospital Centre Zagreb
-
-
-
-
-
Barakaldo, Spanien, 48903
- Hospital Universitario de cruces
-
Madrid, Spanien, 28222
- Hopsital universidad puerta de hierro
-
Madrid, Spanien, 28034
- Ramon y Cajal hospital
-
Oviedo, Spanien, 33011
- Unversitario Central de Asturias
-
Valladolid, Spanien, 47003
- Hospital Clinico Universitario de Valladolid
-
-
-
-
-
München, Tyskland, 81377
- Munich LMU University
-
-
-
-
-
Salzburg, Østrig, A-5020
- Universitätsklinik für Neurologie
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients with an intracranial aneurysm treated with silk vista and silk vista baby.
Beskrivelse
Inclusion Criteria:
- Patient with intracranial aneurysms intended to be treated with the silk vista and silk vista baby (decision of use silk vista and silk vista baby is done independently and prior to the participation of the patient in the study)
- Patients with recanalized aneurysms previously treated with coils exclusively are also eligible.
- In case of multiple aneurysms, only treatment with silk vista and silk vista baby are allowed (between the initial index procedure to the 12 months follow up visit)
- Patient ≥ 18 years, who signed an informed consent.
Exclusion Criteria:
- Patient presenting with contra-indications to the use of silk vista and silk vista babyaccording to the IFU (Instruction for Use).
- Recanalized aneurysms initially treated with stent (including stent assisted coiling)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.
Tidsramme: At 12-months (-3 / + 6 months) post procedure
|
Characterized by the rate of the permanent neurologic deficits and procedure related mortality. |
At 12-months (-3 / + 6 months) post procedure
|
|
Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.
Tidsramme: At 12-months (-3 / + 6 months) post procedure
|
Characterized by the clinical outcome assessed by mRS of the permanent neurologic deficits and procedure related mortality. |
At 12-months (-3 / + 6 months) post procedure
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety of silk vista and silk vista baby
Tidsramme: At T0
|
Assessed by the rate of adverse events |
At T0
|
|
Safety of silk vista and silk vista baby
Tidsramme: At hospital discharge
|
Assessed by the rate of adverse events |
At hospital discharge
|
|
Safety of silk vista and silk vista baby
Tidsramme: Up to 30 days (-10 / + 21 days) post- procedure.
|
Assessed by the rate of adverse events |
Up to 30 days (-10 / + 21 days) post- procedure.
|
|
Safety of silk vista and silk vista baby
Tidsramme: At 6 months (-2/+3 months) post- procedure.
|
Assessed by the rate of adverse events |
At 6 months (-2/+3 months) post- procedure.
|
|
Safety of silk vista and silk vista baby
Tidsramme: At 12 months (-3/+6 months) post- procedure.
|
Assessed by the rate of adverse events |
At 12 months (-3/+6 months) post- procedure.
|
|
Safety of silk vista and silk vista baby
Tidsramme: At 3 years post procedure
|
Assessed by the rate of adverse events |
At 3 years post procedure
|
|
Safety of silk vista and silk vista baby
Tidsramme: At 5 years post procedure
|
Assessed by the rate of adverse events |
At 5 years post procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: At T0
|
Assessed by aneurysm occlusion rate |
At T0
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: At hospital discharge
|
Assessed by aneurysm occlusion rate |
At hospital discharge
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: Up to 30 days (-10 / + 21 days) post- procedure.
|
Assessed by aneurysm occlusion rate |
Up to 30 days (-10 / + 21 days) post- procedure.
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: Up to 6 months (-2/+3 months) post- procedure
|
Assessed by aneurysm occlusion rate |
Up to 6 months (-2/+3 months) post- procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: Up to 12 months (-3 / + 6 months) post procedure
|
Assessed by aneurysm occlusion rate |
Up to 12 months (-3 / + 6 months) post procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: Up to 3 years post procedure
|
Assessed by aneurysm occlusion rate |
Up to 3 years post procedure
|
|
Efficacy of silk vista and silk vista baby
Tidsramme: Up to 5 years post procedure
|
Assessed by aneurysm occlusion rate |
Up to 5 years post procedure
|
|
Technical procedure
Tidsramme: At T0
|
The practices related to the use of silk vista baby will be describe |
At T0
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Mario Martinez Galdamez, Dr, Hospital Clinico Universitario de Valladolid (HCUV), Spain
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CIP 201802 SILK VISTA
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .